Trading was light with 484K shares changing hands on Tuesday. Volume was down 63.92% under the stocks average daily volume.
Traders are feeling more bearish recently as indicated by the motion in short interest. The firm realized a rise in short interest of 10.92% as of October 13, 2017 from the last reporting period. Short shares grew 291,957 over that timeframe. Days to cover decreased -13.0 to 2.0 and the percentage of shorted shares is 0.10% as of October 13.
The following firms have recently changed their position in TROV. Prospera Financial Services Inc downsized its ownership by selling 5,875 shares a decrease of 4.4%. Prospera Financial Services Inc currently owns 126,350 shares with a value of $87,000. The value of the position overall is down by 44.2%. As of quarter end Meeder Asset Management Inc had acquired a total of 1,018 shares growing its position 65.1%. The value of the investment in (TROV) decreased from $2,000 to $2,000 decreasing 0.0% quarter over quarter.
As of the end of the quarter TCI Wealth Advisors, Inc. had bought 400 shares growing its holdings by 133.3%. The value of the investment in TrovaGene, Inc. went from $0 to $1,000 a change of $1,000 since the last quarter. Simplex Trading, LLC grew its position by buying 3,472 shares an increase of 282.7% as of 09/30/2017. Simplex Trading, LLC owns 4,700 shares valued at $3,000. The total value of its holdings increased 200.0%.
The company is down by 2.11% percent from yesterday’s close. The stock is trading at $0.71 which is marginally under the 50 day moving average which is $0.75 and a great deal lower than the 200 day moving average of $0.86. The 50 day moving average went down $-0.04 or -5.5731% and the 200 day average was down $-0.15.
In the latest earnings report the EPS was $-1.25 and is estimated to be $-0.86 for the current year with 37,269,000 shares presently outstanding. Next quarter’s EPS is estimated at $-0.14 and the next full year EPS is anticipated to be $-0.73.
Trovagene, Inc. (TrovaGene), launched on September 21, 2009, is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. The Company has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer..